Summary
Hawthorn (Crataegus) has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Hypertension. ClinicalTrials.gov lists 1 registered trial linking Hawthorn (Crataegus) to Hypertension: 1 has completed. The most advanced is Phase 2 (NCT02419235). It plans or enrolled 30 participants. Registered activity dates to 2014. The literature layer holds 1 publication for this pair: 1 clinical trial publication. The dated items are from 2006. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Essential Hypertension ranks 376 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Not well-characterized as population baseline; routinely framed as irreversible in clinical culture despite contrary trial evidence.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 10.5 (trials 3.5, literature 2.0, tier 5, approved bonus 0.0) |
| Registered trials | 1 total: 0 recruiting, 0 active / not yet recruiting, 1 completed, 0 other |
| Linked publications | 1 (1 clinical trial publication) |
| Agent type | Supplement (Herbal) |
| Development stage (any indication) | Preclinical |
| Mechanism / class | Herbal antihypertensive interventions: a narrative review · Halma M, et al. · 2024 |
| Data sources | OSMF Chronic Disease Review |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT02419235 | The Effect of a Homoeopathic Complex on Blood Pressure in Refractory Hypertension 2014 | completed | Phase 2 | 30 |
Published literature
- Clinical trial publication Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trialWalker AF, Marakis G, Simpson E et al. · The British journal of general practice : the journal of the Royal College of General Practitioners · 2006 · PMID 16762125
Mechanism and notes
Recorded mechanism or class: Herbal antihypertensive interventions: a narrative review · Halma M, et al. · 2024.
OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Hawthorn (Crataegus) approved for Hypertension?
Hawthorn (Crataegus) has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Hypertension. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Hawthorn (Crataegus) in clinical trials for Hypertension?
ClinicalTrials.gov lists 1 registered trial linking Hawthorn (Crataegus) to Hypertension: 1 has completed. The most advanced is Phase 2 (NCT02419235). It plans or enrolled 30 participants. Registered activity dates to 2014.
What does the evidence show for Hawthorn (Crataegus) in Hypertension?
Hawthorn (Crataegus) has 1 completed trial and 1 linked publication for Hypertension. Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.